CAR as Booster to Launch Allogeneic Transplantation in Refractory Leukemia | NEJM
Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with relapsed or refractory B-cell lymphoid cancers.1 With studies showing that more than 5…